#1 New Release on Amazon in Business Ethics: a detailed blueprint for driving purpose through profit––building a business AND a mission simultaneously.
NAPERVILLE, ILLINOIS, USA, March 14, 2023 /EINPresswire.com/ — Trail-blazing social entrepreneurs are tackling the world’s most pressing problems that government, business, or charity have failed to solve. Scott Boyer is one such social entrepreneur. This 28-year veteran of Big Pharma left a six-figure salary to start OWP Pharmaceuticals and the ROW Foundation. This model combines a multimillion-dollar business that fuels a global health nonprofit that’s on track to become the largest funder of projects serving people with epilepsy and associated psychiatric disorders in the world.
Ranked as the #1 New Release on Amazon in Business Ethics, Powering Social Enterprise offers a detailed blueprint for driving purpose through profit––how to launch, grow, sustain, and scale a business AND a mission simultaneously. Students, professors, aspiring social entrepreneurs, and experienced business leaders will find value in this unique approach to building a social enterprise that will last.
SCOTT BOYER is the Founder and CEO of OWP Pharmaceuticals and the Founder and Chairman of ROW Global Health.
JEREMY GUDAUSKAS taught social entrepreneurship at North Central College in Naperville, Illinois where he founded the Center for Social Impact.
MIKE HAMEL has helped more than 100 entrepreneurs and C-level business men and women share their stories with a wider audience.
“The tandem hybrid structure introduced in this book shows the power of leveraging financial resources for purpose in any industry.”— Esther Benjamin, CEO, World Education Services
- Ranked as #1 NEW RELEASE on Amazon.com
- Published by Routledge, Taylor and Francis Group; New York and London
- Available online: https://www.amazon.com/Powering-Social-Enterprise-Profit-Purpose/dp/103235237X/
- Learn more at: https://tandemhybrid.co
This press release can be viewed online at: https://www.einpresswire.com/article/621750154/powering-social-enterprise-with-profit-and-purpose-the-tandem-hybrid-by-scott-boyer-jeremy-gudauskas-and-mike-hamel
OWP has applied for U.S. patent protection for the first-ever oral solution of trazodone, the sixth liquid medication that the company hopes to commercialize.
NAPERVILLE, ILLINOIS, USA, November 30, 2022 /EINPresswire.com/ — OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations. OWP announced today that it has applied for U.S. patent protection for the first-ever oral solution of trazodone hydrochloride. Offering an important delivery alternative for a drug often used for major depressive disorder (MDD), this represents the sixth of several oral liquid medications in neuroscience that the company hopes to commercialize over the next several years via a 505(b)(2) application, in keeping with its pipeline of reformulated, approved therapeutics with no currently available liquid formulation.
Trazodone hydrochloride is a selective serotonin reuptake inhibitor and the tablets, for oral use, were first approved in the U.S. in 1981. The medication is widely prescribed by healthcare providers in psychiatry for MDD, and it is indicated for treatment in adults. The efficacy and safety of trazodone hydrochloride was established from both inpatient and outpatient trials of the trazodone immediate release formulation in the treatment of major depressive disorder. (1) In tablet form, total U.S. prescriptions for trazodone hydrochloride are approximately 35.8 million annually. (2)
Scott Boyer, founder, and chief executive officer of OWP stated, “Today we are pleased to have filed a patent application for our unique formulation of a drug widely used in neuroscience for patients challenged with MDD. As with our other potential entrants, this alternative dosage form may be preferred by patients who have trouble swallowing tablets or who experience swallowing difficulties. Healthcare providers may also find that in this form, the medication may simplify dosage titration or combination therapy. This sixth important strategic initiative, closely following the releases of our oral liquid formulations for lamotrigine, topiramate, quetiapine, atomoxetine, and duloxetine, aligns well with our goal of expanding our business model to include more complex 505(b)(2) branded products in our pipeline.”
Established in 2014, OWP Pharmaceuticals (www.owppharma.com) delivers quality branded and generic neuroscience medications. Its strategic focus is to support neurologists, psychiatrists, and patients in the U.S. with commonly used products, and to donate a significant portion of the profits to the ROW Foundation (www.rowglobal.org) for the provision of resources to those living with epilepsy and associated psychiatric disorders in under-resourced areas of the world.
Cautionary Note Regarding Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company’s management. All statements, other than statements of historical facts, included in this press release, including the Company’s belief of the clinical efficacy and safety of trazodone hydrochloride oral liquid formulation and its ability to improve upon existing treatment options, are forward-looking statements. You should not place undue reliance on the Company’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For further information, contact Scott Boyer, Chief Executive Officer, at Scott.Boyer@owppharma.com.
SOURCE OWP Pharmaceuticals, Inc.
Copyright (C) 2022 (EIN PRESSWIRE). All rights reserved.
- DESYREL® (trazodone hydrochloride) tablets, for oral use. Full prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018207s032lbl.pdf. Accessed November 15, 2022.
- Symphony Health Data. One year rolling average ending September 2022.
Scott Boyer, CEO
OWP Pharmaceuticals, Inc.
Visit us on social media: LinkedIn
This press release can be viewed online at: https://www.einpresswire.com/article/603099900
CHICAGO — January 5, 2022 — OWP Pharmaceuticals, Inc. is a privately held, neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations and supporting global philanthropy. Today OWP announced its partnership with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to launch and commercialize its portfolio of oral liquid formulations aimed to treat neuroscience disorders.
Pending regulatory approvals, OWP has multiple specialty pharmaceutical products in development. Most recently, OWP announced IND authorization for the first-ever oral liquid formulation of atomoxetine hydrochloride for the treatment of attention deficit hyperactivity disorder. OWP has also received patent issuance or IND authorization for multiple therapies for the treatment of epilepsy, schizophrenia, bipolar disorder, major depressive and generalized anxiety disorder, and migraines.
OWP will utilize many of EVERSANA’s fully integrated commercialization services that include market access, agency services, clinical and commercial field teams, channel management, patient services, health economics and outcomes research, and compliance, with each service optimized by data and predictive analytics.
“With EVERSANA’s integrated commercialization solution, we are ensuring that our products will get to patients efficiently and effectively as we anticipate multiple regulatory approvals in 2023 and beyond,” said Scott Boyer, Founder and President, OWP.
“The unmet need for better neuroscience treatments demands our attention,” said Jim Lang, Chief Executive Officer of EVERSANA. “Our EVERSANA COMPLETE end-to-end commercialization engine will be ready to move swiftly in anticipation of FDA submissions and approvals.”
Established in 2014, OWP Pharmaceuticals’ (www.owppharma.com) focus is to support patients and healthcare providers in neurology and psychiatry in the U.S. with beneficial neuroscience medications, and to donate profits to the ROW Foundation (www.rowpharma.org). ROW seeks to improve the education, diagnosis, and treatment available for those living with neurological and psychiatric disorders in under-resourced areas of the world. In short, OWP uses commercial success for the common good by supporting humanitarian projects in many countries. To learn more about OWP and ROW, visit owppharma.com and rowpharma.org or connect through LinkedIn and Twitter.
EVERSANA™ is the leading provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life science solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter.
Cautionary Note Regarding Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the company’s management. All statements, other than statements of historical facts, included in this press release, including the company’s belief of the clinical efficacy and safety of any oral liquid formulations and their ability to improve upon existing treatment options, are forward-looking statements. You should not place undue reliance on the company’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. The forward-looking statements are made as of this date and the company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Chief Executive Officer, OWP
Chief Marketing and Corporate Communications Officer, EVERSANA